{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Cardiff Oncology, Inc. technically bullish or bearish?
As of June 17, 2025, the market trend has shifted to mildly bearish, influenced by daily moving averages and weekly Bollinger Bands, despite some indicators like the MACD showing mild bullishness.
Who are in the management team of Cardiff Oncology, Inc.?
As of March 2022, the management team of Cardiff Oncology, Inc. includes Dr. Rodney Markin (Chairman), Dr. Mark Erlander (CEO), and several independent directors: Dr. Thomas Adams, Dr. James Armitage, Dr. Paul Billings, Mr. John Brancaccio, and Dr. Gary Jacob. This team provides governance and strategic direction for the company.
What does Cardiff Oncology, Inc. do?
Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing cancer treatments. As of March 2025, it has a market cap of $246.15 million, with net sales of $0 and a net loss of $13 million.
How big is Cardiff Oncology, Inc.?
As of Jun 18, Cardiff Oncology, Inc. has a market capitalization of 246.15 million, with net sales of 0.59 million and a net profit of -48.86 million over the latest four quarters. The company reported shareholder's funds of 82.95 million and total assets of 97.19 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
